Back

Past webinar

Medical Affairs Insights and Learnings for and after Covid-19

Speakers

Oleksandr Gorbenko

Oleksandr Gorbenko

Global Patient Centricity Director

Manfred Melzer

Manfred Melzer

Head of Pharma Affairs

Marijo Jurasovic

Marijo Jurasovic

Managing Director

Jose Antonio Buron Vidal

Jose Antonio Buron Vidal

Europe Regional Medical Head

Gabriella Salvatore

Gabriella Salvatore

Moderator

Medical Affairs like every other pharma function goes through some incremental changes due to the Covid-19 escalation. The Webinar gathers leading pharma and healthcare-IT champions who will showcase some insights and learnings for and after the Covid-19 period.

  • Get up to date/meaningful/real-world insights from patient needs
  • How Covid-19 impacted the patient world
  • Understand patient initiatives and perspectives
  • Hear the real patient voice and what has to change to develop a proper patient engagement model

Join our complimentary webinar and look into the insights and key learnings from Medical Affairs. Among the many questions and challenges we will discuss:

  • Predictive approaches to avoid drug therapy risks proactively in times of COVID-19
  • Options for drug therapy
  • Opportunities and risks of off-label use for the treatment of COVID-19
  • Dealing with uncertainties of insufficient evidence-based information and perspectives for avoiding COVID-19-related risks in drug therapy
  • How the use of the proper digital channels can help to provide physicians with fast, valid information on risks and precautions of drug therapies in combination with COVID-19

 

Date: Tuesday, 15 June 2020
Time: 3 PM CET

Our media partner is pharmaphorum

This webinar is initiated by MMI/VIDAL Group in cooperation with M3 and NEXT Pharma Summit. VIDAL Group platforms are unique as they’re a mix of regulatory content enriched with scientific treatment-related content at the point of care. This is a unique opportunity for the Pharmaceutical industry to gain unique insights of real-life physician behavior and address HCPs with regulatory/scientific content.

Watch video